Novel aldose reductase inhibitors: A patent survey (2006 present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 11, 2012, Pages 1303-1323

  Chatzopoulou, Maria ^a   Alexiou, Polyxeni ^a,b   Kotsampasakou, Eleni ^a   Demopoulos, Vassilis J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aldose reductase (ALR2); Aldose reductase inhibitors (ARIs); Cancer; Inflammation; Long term diabetic complications

Indexed keywords

ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BIRCH EXTRACT; CAFFEIC ACID DERIVATIVE; CHAMOMILE; CRYPTOMERIA JAPONICA EXTRACT; DIMORPHANDRA MOLLIS EXTRACT; EPALRESTAT; ERYTHROXYLUM CATUABA EXTRACT; EUPHRASIA EXTRACT; FAGUS CRENATA EXTRACT; FARGUS CRENATA EXTRACT; FIDARESTAT; FOMITOPSIS PINICOLA EXTRACT; LARCHES EXTRACT; LARIX GMELINII EXTRACT; NELUMBO NUCIFERA EXTRACT; ONION EXTRACT; PEANUT EXTRACT; PLANT EXTRACT; PLUM TREE EXTRACT; PTEROCARYA RHOIFOLIA EXTRACT; PTERRCARYA RHOIFOLIA; QUERCUS ACUTISSIMA EXTRACT; QUERCUS EXTRACT; QUINIC ACID; RANIRESTAT; SAWTOOTH OAK TREE EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CANCER INHIBITION; CRYSTAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; GLUCOSE METABOLISM; HUMAN; INFLAMMATORY DISEASE; NEOPLASM; NONHUMAN; PATENT; PATHOLOGY; PHYSICAL CHEMISTRY; PROTEIN DOMAIN; REVIEW; SEPSIS;

ALDEHYDE REDUCTASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867752191     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.726615     Document Type: Review

References (98)

1. Hers HG. Aldose reductase. Biochim Biophys Acta 1960;37:120-6
2. Alexiou P, Pegklidou K, Chatzopoulou M, et al. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 2009;16:734-52
3. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26:380-92
4. Ramana KV, Srivastava SK. Aldose reductase: A novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 2010;42:17-20
5. Tammali R, Srivastava SK, Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets 2011;11:560-71
6. Del Corso A, Cappiello M, Mura U. From a dull enzyme to something else: Facts and perspectives regarding aldose reductase. Curr Med Chem 2008;15:1452-61
7. Zentgraf M, Steuber H, Koch C, et al. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase. Angew Chem Int Ed 2007;46:3575-8
8. Balendiran GK, Sawaya MR, Schwarz FP, et al. The role of cys-298 in aldose reductase function. J Biol Chem 2011;286:6336-44
9. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003;52:864-71
10. Alexiou P, Chatzopoulou M, Pegklidou K, et al. RAGE: A multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010;17:2232-52
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20
12. Nishikawa T, Edelstein D, Brownlee M. The missing link: A single unifying mechanism for diabetic complications. Kidney Int 2000;77:S26-30
13. Vincent AM, Russell JW, Low P, et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004;25:612-28
14. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008;9:14-36
15. Obrosova IG, Kador PF. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol 2011;12:373-85
16. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 2009;11:e13
17. Pandey S, Srivastava SK, Ramana KV. A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opin Investig Drug 2012;21:329-39
18. Ramana KV. Aldose reductase: New insights for an old enzyme. Bio Mol Concepts 2011;2:103-14
19. Srivastava SK, Ramana KV; University of Texas System, USA. Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use. US20070021366A1; 2007
20. Srivastava SK, Ramana KV; The Board of Regents of the University of Texas System, USA. Methods and compositions using aldose reductase inhibitors for the treatment of inflammation. WO2008118844A1; 2008
21. Srivastava SK, Ramana KV; The Board of Regents of the University of Texas System, USA. Methods involving aldose reductase inhibition. US20090270490A1; 2009
22. Srivastava SK, Ramana KV; USA. Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use. US20100022625A1; 2010
23. Srivastava SK, Ramana KV; University of Texas System, USA. Treatment of cancer with aldose reductase inhibitors. US20110092566A1; 2011
24. Srivastava SK, Ramana KV, Bhatnagar A; Board of Regents, The University of Texas System, USA. Methods involving aldose reductase inhibitors. US20060293265A1; 2006
25. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy - A 52-week multicenter placebo-controlled doubleblind parallel group study. Diabetes Care 2001;24:1776-82
26. Daiichi Sankyo Co. Ltd. Group Research & Development Pipeline. 2006
27. Wang S, Yan J, Wu J, et al. Shenyang Pharmaceutical University, Peop. Rep. China; Chengdu Diao Pharmaceutical Group Co., Ltd. Preparation of 4-oxo-1 (4H)-quinolinecarboxylic acid derivatives as aldose reductase inhibitors. CN101058558A; 2007
28. Toyooka N, Kato A, Adachi I; National University Corp. University of Toyama, Japan. Preparation of fused tricyclic compounds as aldose reductase inhibitors. WO2009078423A1; 2009
29. Stefek M, Snirc V, Demopoulos VJ, et al. Ustav Experimentalnej Farmakologie SAV, Slovakia. Use of carboxymethylated pyridoindoles and pharmaceutical composition containing them. SK286958B6; 2009
30. Stefek M, Snirc V, Djoubissie PO, et al Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling. Bioorg Med Chem 2008;16:4908-20
31. Djoubissie PO, Snirc V, Sotnikova R, et al. In vitro inhibition of lens aldose reductase by (2-benzyl-2,3,4,5- tetrahydro-1H-pyrido[4,3-b]indole-8-yl)- acetic acid in enzyme preparations isolated from diabetic rats. Gen Physiol Biophys 2006;25:415-25
32. Stefek M, Tsantili-Kakoulidou A, Milackova I, et al. (2-Benzyl-2,3,4,5- tetrahydro-1H-pyrido[4,3-b]indol-8-yl)- acetic acid: An aldose reductase inhibitor and antioxidant of zwitterionic nature. Bioorg Med Chem 2011;19:7181-5
33. Juskova M, Snirc V, Gajdosikova A, et al. Carboxymethylated tetrahydropyridoindoles as aldose reductase inhibitors: In vitro selectivity study in intact rat erythrocytes in relation to glycolytic pathway. Gen Physiol Biophys 2009;28:325-30
34. Hua DH; Kansas State University Research Foundation, USA. Tricyclic pyrones as aldose reductase inhibitors. US7935726B1; 2011
35. Kulkarni SA, Gollapudy RR, Deshpande SK; Vlife Sciences Technologies Pvt. Ltd., India. Pharmaceutical composition comprising beta-blocker for treatment of diabetic complications by aldose reductase inhibition. WO2008093356A1; 2008
36. Zhu C, Xu D, Peng J, et al. Beijing Institute of Technology, Peop. Rep. China. Structure and synthesis of aldose reductase inhibitor. CN101143869A; 2008
37. Zhu C, Xu D, Peng J, et al. Beijing Institute of Technology, Peop. Rep. China. Structure and application of aldose reductase inhibitor. CN101143868A; 2008
38. Chung SK, Chung S, Hibi C; Sanwa Kagaku Kenkyusho Co., Ltd., Japan. Aldose reductase inhibitors as protective agents for retinal nerve or optic nerve. WO2008093691A1; 2008
39. Wasmuth A, Landry DW, Deng SX, et al. Columbia University, USA. Preparation of oxodihydropyrazinopyridazine derivatives for use as aldose reductase inhibitors. WO2012009553A1; 2012
40. Pegklidou K, Nicolaou I, Demopoulos VJ. Nutritional overview on the management of type 2 diabetes and the prevention of its complications. Curr Diabetes Rev 2010;6:400-9
41. Kamiya S, Aoyama K; TDK Corp., Japan. An aldose reductase inhibitor and manufacturing method of the same. JP2006001853A; 2006
42. Kamiya S, Aoyama K, Tanaka K; TDK Corp., Japan. Aldose reducase inhibitor prepared from stem or branch of Fagus Sylvatica, Lignum Pterocarpi Indici and Japanese wingnut. JP2006036663A; 2006
43. Kamiya S, Aoyama K, Tanaka K; Tdk Corp., Japan. Gymnosperm tree extracts as aldose reductase inhibitors. JP2006028093A; 2006
44. Suwa Y, Koda H, Haraguchi H; Suntory Ltd, Japan. Aldose reductase inhibitor. WO2006030898A1; 2006
45. Ono M; USA. Plant extract compositions for treating diabetes or obesity. WO2006074278A2; 2006
46. Yoshikawa M; Nihon Yakuyo Shokuhin Kenkyusho K. K., Japan; Harima Kanpo Seiyaku K. K. Saponin-containing tea flower extracts, pharmaceutical compositions, and health foods for absorption inhibition of neutral lipids and sugar, and gastric mucosal membrane protection. JP2006070018A; 2006
47. Choi JS, Jung YJ, Lim SS; Pukyong National University, Business Incubator Center, S. Korea. Composition containing extract or separated compounds of Nelumbo nucifera stamen and used for preventing and treating diabetic complication. KR747640B1; 2007
48. Du Z, Zhang K, Fang Y, et al. Guangdong University of Technology, Peop. Rep. China. Application of tanshinone derivatives on preparation of aldose reductase inhibitors. CN101012270A; 2007
49. Oh S-H, Kim S-D, Lee S-I, et al. Eugene Bio.Farm Co. Ltd., S. Korea. Fomitopsis pinicola extract for inhibiting aldose reductase activity and a process for manufacturing the same. WO2007078157A1; 2007
50. Yoshimoto M, Kurata R, Takagaki K, et al. National Agriculture Bio-Oriented Research Organization, Japan; Toyo Shinyaku Co., Ltd. Pharmaceuticals for prophylactic or therapeutic treatment of diabetes or its complications, and food compositions containing them. JP2007119346A; 2007
51. Surolia A, Sharma SK, Surolia N, et al. National Institute of Immunology and Indian Institute of Science, India. Synergistic composition for modulating activity of substrate analogs for NAD+/ NADP+ or NADH/NADPH dependent enzymes and process thereof. US20080161247A1; 2008
52. Surolia A, Surolia N, Sharma SK, et al. National Institute of Immunology, India; Indian Institute of Science A Registered Trust, In India, Under Charitable Endowments Act. Synergistic composition for modulating activity of substrate analogs for NAD+, NADP+, NADH or NADPH dependent enzymes for treatment of malaria and other infectious diseases. EP1938841A2; 2008
53. Kojima H; Kobayashi Pharmaceutical Co., Ltd., Japan. Aldose reductase inhibitors containing plant processed products, and pharmaceutical compositions and food containing them. JP2009084198A; 2009
54. Yoshikawa M; NTH K. K., Japan. Flavan dimers, natural henna extracts containing them, and pharmaceutical compositions containing the compounds or the extracts, and their uses. JP2009091315A; 2009
55. Janaswamy MR, Geereddy BR, Vidadala RSR, et al. Council of Scientific & Industrial Research, India. Aldose reductase 2 nhibitors and their synthesis from a natural source. WO2011117706A1; 2011
56. Tomatsu S, Sugimoto H, Shindo A; Akita Prefecture, Japan. Aldose reductase inhibitors from fruit wine. JP2007031326A; 2007
57. Lewis R; USA. Composition comprising mushroom extract for reducing or preventing pain. US20080031891A1; 2008
58. Kalofonos I, Stahly GP, Martin-Doyle W, et al. Bionevia Pharmaceuticals, Inc., USA. Preparation of crystalline anhydrate salts of epalrestat. WO2010011922A2; 2010
59. Kalofonos I, Stahly GP, Martin-Doyle W, et al. Bionevia Pharmaceuticals, Inc., USA. Novel solid forms of epalrestat. US20110275681A1; 2011
60. Kalofonos I, Stahly GP, Martin-Doyle W, et al. Bionevia Pharmaceuticals, Inc., USA. Preparation of novel choline cocrystal of epalrestat and therapeutic uses thereof. WO2010028132A2; 2010
61. Kalofonos I, Stahly PG, Martin-Doyle W, et al. Bionevia Pharmaceuticals, Inc., USA. Betaine co-crystal of epalrestat. WO2010011926A2; 2010
62. Olthof MR, Brink EJ, Katan MB, et al. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Am J Clin Nutr 2005;82:111-17
63. Setoue M, Ohuchi S, Morita T, et al. Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats. Biosci Biotech Biochem 2008;72:1696-703
64. Wong VG, Wood LL; Ramscor, Inc., USA. Conveniently implantable sustained release drug compositions. US20080038316A1; 2008
65. Wong VG, Wood LL; Ramscor, Inc., USA. Sustained release eye drop formulations. US20090136445A1; 2009
66. Hezi-Yamit A; Medtronic Vascular, Inc., USA. Medical devices to treat or inhibit restenosis. US20060062822A1; 2006
67. Isozaki M, Nozawa S; Terumo Corp., Japan. Amidines and their use for drug carriers. JP2007091657A; 2007
68. Koiwai K, Sakaguchi N, Kono K; Terumo Corp., Japan; Osaka Prefecture University. Pharmaceutical carriers containing amidine derivatives and polyglycidol derivatives. JP2008120718A; 2008
69. Sakurai K, Kusunoki S, Hamada E, et al. Japan Science and Technology Agency, Japan; Kitakyushu Foundation for the Advancement of Industry, Science and Technology Collaboration Center; Terumo Corp. Preparation of arylmethylamines and their use as drug carriers. JP2008105961A; 2008
70. Yoo H-O, Son T-W; Genic Co., Ltd., S. Korea. Dissolvable nano-web porous film comprising a nano-fiber forming polymer and a gelling agent. WO2009022761A1; 2009
71. Geho BW, Lau JR; SDG, Inc. An Ohio Corp., USA. Insulin therapies for the treatment of diabetes and other disorders. WO2010080976A1; 2010
72. Dutt C, Joshi D, Gupta R, et al. Torrent Pharmaceuticals Ltd., India. Pharmaceutical combinations comprising a pyridinium compound for treatment of diabetic complications. WO2009093264A2; 2009
73. Messadek J; Messadek, Jallal, Belg. Combination therapeutic compositions comprising betaines and antidiabetics. WO2006086856A1; 2006
74. Messadek J; Belg. Combination therapy for diabetes mellitus comprising betaines. US20080031964A1; 2008
75. Boatman DP, Schrader TO, Semple G, et al. Arena Pharmaceuticals, Inc., USA. Fused pyrazole derivatives and their preparation, pharmaceutical compositions, and methods for treatment of metabolic-related disorders. WO2006069242A2; 2006
76. Tsuno M, Hanada T; Eisai R & D Management Co., Ltd., Japan. AMPA receptor antagonists and aldose reductase inhibitors for neuropathic pain. WO2009011410A1; 2009
77. Takeda H, Kiguchi S; Kissei Pharmaceutical Co., Ltd., Japan. Pharmaceutical composition for prevention or treatment of neurogenic pain. WO2007061114A1; 2007
78. Castel JC, Palermo FX; Accelerated Care Plus Corp., USA. Electrical stimulation method for treatment of peripheral neuropathy. US20090326607A1; 2009
79. Kador PF; USA. Periodontitis treatment with aldose reductase inhibitor. US20100292287A1; 2010
80. Kador PF, O'Meara JD, Blessing K, et al. Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats. J Periodontol 2011;82:926-33
81. Kador PF, Wyman M, Betts DM; USA. Formulation comprising aldose reductase inhibitor such as 2R-Me sorbinil for topical treatment of cataracts in dogs. US20090082415A1; 2009
82. Kador PF, Wyman M, Betts DM; USA. Topical treatment of cataracts in dogs. WO2010065024A1; 2010
83. Urban FJ; Pfizer, Inc., USA. Process for the production of asymmetric hydantoins. US4841079A; 1989
84. Kador PF, Betts D, Wyman M, et al. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. Am J Vet Res 2006;67:1783-7
85. Kador PF, Randazzo J, Babb T, et al. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther 2007;23:116-23
86. Chung SK, Chung S, Hibi C; Sanwa Kagaku Kenkyusho Co., Ltd., Japan. Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke. US20090076105A1; 2009
87. Miyamoto S. Recent advances in aldose reductase inhibitors: Potential agents for the treatment of diabetic complications. Expert Opin Ther Patents 2002;12:621-31
88. De la Fuente JA, Manzanaro S. Aldose reductase inhibitors from natural sources. Nat Prod Rep 2003;20:243-51
89. Jung M, Park M, Lee HC, et al. Antidiabetic agents from medicinal plants. Curr Med Chem 2006;13:1203-18
90. Shimoda H, Aitani N, Okada T, et al. Oryza Oil & Fat Chemical Co., Ltd., Japan. Aldose reductase inhibitors containing polyphenols, and diabetic complication-preventing compositions containing the same. JP2006335752A; 2006
91. Terasawa K, Adachi I, Kato A; Japan. Evodiae fructus extracts containing N,Ndimethyl- 5-methoxytryptamine as aldose reductase inhibitors and antidiabetics. JP2006022102A; 2006
92. Lim SS, Kang IJ, Shin HK; Hallym University, S. Korea. Zingiberaceae (Alpinia officinarum) extract for therapy of diabetic complications. KR2007063760A; 2007
93. Kang IJ, Lim SS, Park JS, et al. Hallym University Industry -Academic Cooperation Foundation, S. Korea; Chuncheon Bioindustry Foundation; Seorim Bio Co., Ltd. Composition containing Elsholtzia ciliate extract for inhibiting diabetes complicating diseases. KR857691B1; 2008
94. Lu C, Zhou S, Zhang R, et al. Second Affiliated Hospital, Third Military Medical University, Peop. Rep. China. Medicinal composition comprising arctiin or arctigenin for treating diabetic cardiovascular diseases and its preparation method. CN101278940A; 2008
95. Xu C, Jia W, Feng Y; Shanghai University of Traditional Chinese Medicine, Peop. Rep. China. Method for manufacturing extracts of Chinese medicine Arctium for preventing and treating diabetes mellitus complication. CN101766668A; 2010
96. Miyazaki T, Kitajima C, Okuyama T, et al. Nagase & Co., Ltd., Japan. Aldose reductase inhibitor containing marine algae extract, and production thereof. JP2008214245A; 2008
97. Ouyang D, Wang J, Yan J, et al. Peop. Rep. China. Application of Eucommia ulmoides lignans in preventing and treating diabetic complications. CN101138578A; 2008
98. Li N, Li X, Meng D, et al. Shenyang Pharmaceutical University, Peop. Rep. China. Extraction method of novel 9,19-cycloartane triterpenoids from Chinese medicine Camptosorus and its application thereof. CN101851266A; 2010